Physician profile
Robert Tracy
NPI 1316219058
$2,173.99
in general payments reported to CMS, 2019-2025
14 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $502 · 2021: $440 · 2022: $142 · 2023: $206 · 2024: $140 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $529.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $416.81 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $411.17 | 2019-2022 | |
| Novo Nordisk INC | $379.78 | 2019-2023 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $237.18 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $166.27 | 2020-2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $122.60 | 2019-2023 | Januvia, Steglatro, Belsomra |
| Glaxosmithkline, LLC. | $107.85 | 2019-2024 | Trelegy Ellipta |
| Amgen INC. | $97.06 | 2025 | Repatha |
| Fidia Pharma USA INC. | $70.25 | 2019-2023 | Triluron, Hymovis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.90 | 2021 | |
| Amarin Pharma, INC. | $39.41 | 2020 | |
| Gilead Sciences, INC. | $33.95 | 2020 | |
| Nestle Healthcare Nutrition INC. | $24.47 | 2020 | |
| Merz North America, INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tracy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.